Apellis Stock Today

APLS
 Stock
  

USD 50.96  1.98  4.04%   

Market Performance
0 of 100
Odds Of Distress
Less than 3
Apellis Pharmaceuticals is selling at 50.96 as of the 26th of November 2022; that is 4.04 percent increase since the beginning of the trading day. The stock's lowest day price was 48.61. Apellis Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Apellis Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of June 2021 and ending today, the 26th of November 2022. Click here to learn more.
CUSIP
03753U106
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
9th of November 2017
Category
Healthcare
Classification
Health Care
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company has 110.58 M outstanding shares of which 9.73 M shares are presently shorted by private and institutional investors with about 7.58 trading days to cover. More on Apellis Pharmaceuticals

Moving against Apellis Pharmaceuticals

-0.77MRNAModerna Potential GrowthPairCorr
-0.75XOMExxon Mobil Corp TrendingPairCorr
-0.72TWTRTwitter DelistingPairCorr
-0.72SUSuncor Energy Potential GrowthPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Apellis Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Apellis Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Apellis Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Apellis Pharmaceuticals generated a negative expected return over the last 90 days
Apellis Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 113.05 M. Net Loss for the year was (634.11 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
Apellis Pharmaceuticals currently holds about 708.55 M in cash with (485.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.41.
Apellis Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 90.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: GSK to slash about 150 consumer commercial jobs in India - FiercePharma
CEOCedric Francois
Average Analyst Recommendation
Analysts covering Apellis Pharmaceuticals report their recommendations after researching Apellis Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Apellis Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Apellis Pharmaceuticals. The Apellis consensus assessment is calculated by taking the average forecast from all of the analysts covering Apellis Pharmaceuticals.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Apellis Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Apellis Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted91.1 M84.4 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares91.1 M84.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities142.3 M131.8 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities737 M683.1 M
Significantly Up
Increasing
Slightly volatile
Gross Margin89.2189.73
Slightly Down
Decreasing
Slightly volatile
Total Debt203.1 M210.2 M
Sufficiently Down
Increasing
Slightly volatile
Asset Turnover0.07410.0723
Fairly Up
Decreasing
Slightly volatile
Current Assets889.1 M824 M
Significantly Up
Increasing
Slightly volatile
Total Assets951.4 M881.8 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Apellis Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Apellis Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Apellis Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Apellis Pharmaceuticals' financial leverage. It provides some insight into what part of Apellis Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Apellis Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Apellis Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Apellis Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 113.37 M in liabilities with Debt to Equity (D/E) ratio of 0.37, which is about average as compared to similar companies. Apellis Pharmaceuticals has a current ratio of 7.07, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Apellis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Apellis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Apellis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Apellis to invest in growth at high rates of return. When we think about Apellis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(577.95 Million)
Apellis Pharmaceuticals (APLS) is traded on NASDAQ Exchange in USA and employs 476 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 5.58 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Apellis Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 110.58 M outstanding shares of which 9.73 M shares are presently shorted by private and institutional investors with about 7.58 trading days to cover. Apellis Pharmaceuticals currently holds about 708.55 M in cash with (485.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.41.
Check Apellis Pharmaceuticals Probability Of Bankruptcy
Ownership
Apellis Pharmaceuticals holds a total of one hundred ten million five hundred eighty thousand outstanding shares. The majority of Apellis Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apellis Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apellis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Apellis Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Also note that nearly five million five hundred twenty-nine thousand invesors are currently shorting Apellis Pharmaceuticals expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Apellis Ownership Details

Apellis Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Apellis Pharmaceuticals jumping above the current price in 90 days from now is about 85.18%. The Apellis Pharmaceuticals probability density function shows the probability of Apellis Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Apellis Pharmaceuticals has a beta of 0.4479. This suggests as returns on the market go up, Apellis Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Apellis Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Apellis Pharmaceuticals is significantly underperforming DOW.
  Odds Below 50.96HorizonTargetOdds Above 50.96
14.74%90 days
 50.96 
85.18%
Based on a normal probability distribution, the odds of Apellis Pharmaceuticals to move above the current price in 90 days from now is about 85.18 (This Apellis Pharmaceuticals probability density function shows the probability of Apellis Stock to fall within a particular range of prices over 90 days) .

Apellis Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Apellis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Apellis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Apellis Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10.4 K471 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares11.6 K591 K
View Apellis Pharmaceuticals Diagnostics

Apellis Pharmaceuticals Historical Income Statement

Apellis Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Apellis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Apellis Pharmaceuticals revenue and expense. Apellis Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Apellis Pharmaceuticals Operating Expenses is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Operating Expenses of 602.64 Million. As of 11/26/2022, Research and Development Expense is likely to grow to about 373.2 M, while Earning Before Interest and Taxes EBIT is likely to drop (752 M). View More Fundamentals

Apellis Stock Against Markets

Picking the right benchmark for Apellis Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Apellis Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Apellis Pharmaceuticals is critical whether you are bullish or bearish towards Apellis Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Apellis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Apellis Pharmaceuticals Corporate Executives

Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Timothy Sullivan - CFO, TreasurerProfile
Daniel Geffken - Interim CFOProfile
Pascal Deschatelets - Co-Founder, COOProfile

Invested in Apellis Pharmaceuticals?

The danger of trading Apellis Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apellis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apellis Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apellis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
2.9
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.